

### Performance of top companies in Mar'26

Company	MAT growth (%)	Mar'26 (%)
IPM	9.9	10.7
Abbott	7.8	11.3
Ajanta	13.1	14.5
Alembic	1.1	-1.4
Alkem	8.7	11.1
Cipla	8.5	5.9
Dr Reddys	12.1	18.2
Emcure	5.1	2.4
Eris	7.4	8.0
Glaxo	6.9	7.8
Glenmark	13.6	12.7
Intas	14.0	15.6
Ipca	10.7	11.1
Lupin	10.5	14.6
Macleods	10.4	9.1
Mankind	8.2	11.5
Sanofi	9.7	11.6
Sun	11.8	12.5
Torrent	10.5	11.3
Zydus	10.1	10.8

### IPM sustains healthy growth, driven by chronic therapies

- The Indian pharma market (IPM) grew 11% YoY in Mar'26, in line with 12% in Feb'26 and 10% in Mar'25.
- Growth was driven by strong outperformance in Cardiac, Anti-diabetic, VMN, and Pain therapies, which exceeded overall IPM growth by 400bp, 300bp, 200bp, and 100bp, respectively, in Mar'26.
- Acute therapies registered 8% YoY growth in Mar'26, a bit softer than 10% YoY in Feb'26 and 9% YoY in Jan'26.
- The chronic therapy segment maintained robust double-digit growth of 14% YoY, supported by increased focus on chronic portfolios amid evolving lifestyle trends in the domestic market.
- For the 12 months ending Mar'26, IPM growth was driven by 2.7%/4.4%/2.8% YoY growth in volumes/prices/new launches.
- Mounjaro remained the top-selling drug in Mar'26 with sales of INR1.2b, followed by Foracort at INR0.9b, according to IQVIA.
- Mixtard continued to decline, reporting a 38% YoY drop in Mar'26, as per IQVIA data.

### DRRD/Intas/Lupin/Glenmark outperform in Mar'26

- Among the top 20 pharma companies, DRRD (+18% YoY), Intas (+16%), Lupin (+15%), and Glenmark (+13%) outperformed the overall IPM in Mar'26.
- Emcure (+2% YoY), Cipla (+6%), Eris (+8%), Glaxo (+8%), and Micro (+8%) were the key underperformers during the month.
- DRRD outperformed IPM, driven by double-digit growth across key therapies.
- Lupin outperformed IPM, led by superior growth in Respiratory/Cardiac.
- Corona Remedies reported industry-leading price growth of 9.1% YoY on MAT basis. Glaxo reported the highest volume growth of 6.8% YoY on MAT basis. Zydus posted the highest growth in new launches at 4.9% YoY on MAT basis.

### Cardiac/Anti-Diabetic/Respiratory lead YoY growth on MAT basis

- On MAT basis, the industry reported 9.9% growth YoY.
- On MAT basis, chronic therapies posted 13.6% YoY growth, while acute therapies recorded 7.5% YoY growth in Mar'26.
- The acute segment's share in overall IPM stood at 59.6% for MAT Mar'26.
- Cardiac/Anti-Diabetic/Respiratory grew by 14.3%/12.2%/11.8%. AI/Gastro /Derma underperformed IPM by ~510bp/340bp/310bp on YoY basis for 12 months ending in Mar'26.

### MNCs continue to outperform domestic companies in YoY growth

- As of Mar'26, Indian pharma companies retained a dominant 83% market share in IPM, with the remainder held by MNCs.
- In terms of growth, Indian companies expanded by 10.1% YoY, while MNCs outpaced them with 13.8% YoY growth in Mar'26.


**Tushar Manudhane - Research Analyst** (Tushar.Manudhane@MotilalOswal.com)

**Eshita Jain - Research Analyst** (Eshita.Jain@MotilalOswal.com) | **Vipul Mehta** (vipul.mehta@motilalosal.com)

**Investors are advised to refer through important disclosures made at the last page of the Research Report.**


Motilal Oswal research is available on [www.motilalosal.com/Institutional-Equities](http://www.motilalosal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

**Exhibit 1: IPM posted 11% YoY growth in Mar'26**




Source: MOFSL, IQVIA

**Exhibit 2: Acute/chronic therapies registered 8%/14% YoY growth**



Source: MOFSL, IQVIA

**Exhibit 3: Indian companies/MNCs reported 14%/10% YoY growth**



Source: MOFSL, IQVIA

## Indian Pharma Market – Mar'26

Exhibit 4: Performance of top companies in Mar'26

Company	MAT Mar'26 value (INR b)	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month
				Jun'24	Sep'24	Dec'24	Mar'25	Jun'25	Sep'25	Dec'25	Mar'26	Mar'26
IPM	2,565	100	9.9	9.0	8.3	7.7	7.5	8.8	7.3	11.9	11.6	10.7
Sun Pharma	207	8.1	11.8	9.2	10.4	10.6	11.0	11.3	7.8	14.7	13.6	12.5
Abbott	162	6.3	7.8	7.8	9.7	10.0	8.4	8.5	6.6	6.8	9.3	11.3
Cipla	144	5.6	8.5	7.4	5.9	6.1	8.7	6.5	7.1	10.6	9.2	5.9
Mankind	122	4.7	8.2	10.8	8.5	5.0	6.1	9.1	6.3	8.8	8.7	11.5
Alkem	100	3.9	8.7	5.9	5.9	5.9	6.0	8.8	6.2	9.3	11.0	11.1
Lupin	88	3.4	10.5	9.8	8.6	6.4	6.2	7.4	5.6	14.2	14.8	14.6
Intas Pharma	97	3.8	14.0	10.9	13.6	9.9	9.7	11.1	9.7	17.5	17.7	15.6
Torrent	119	4.6	10.5	9.0	10.8	9.0	8.6	10.7	7.5	11.7	12.2	11.3
Macleods Pharma	84	3.3	10.4	12.0	3.3	3.7	3.9	7.7	12.6	11.1	9.8	9.1
Dr. Reddys	82	3.2	12.1	8.6	9.4	10.3	5.3	11.0	10.0	12.3	15.2	18.2
Zydus	74	2.9	10.1	9.4	10.8	8.1	9.8	8.7	6.8	13.7	11.0	10.8
GSK	56	2.2	6.9	3.4	0.7	1.3	0.2	3.8	3.0	11.0	9.6	7.8
Glenmark	56	2.2	13.6	15.9	12.3	9.4	10.2	14.7	11.4	16.1	12.5	12.7
Ipca	54	2.1	10.7	14.7	13.4	11.4	13.6	8.6	8.3	12.8	13.6	11.1
Emcure	57	2.2	5.1	6.1	7.3	4.5	5.1	7.3	3.1	6.5	3.7	2.4
Alembic	32	1.3	1.1	5.0	1.3	-1.6	-2.1	2.1	0.1	2.0	0.3	-1.4
Eris Lifesciences	33	1.3	7.4	8.3	4.4	3.5	2.5	4.0	6.4	11.0	8.4	8.0
Ajanta	21	0.8	13.1	11.7	12.3	10.8	7.7	10.6	12.0	14.9	15.1	14.5


Source: IQVIA, MOFSL

Exhibit 5: Cardiac/Anti-Diabetic/VMN drive growth in Mar'26

Therapy	MAT Mar'26 value (INR b)	Market share (%)	Growth (%)	YoY growth (%) in the last eight quarters								One month
				Jun'24	Sep'24	Dec'24	Mar'25	Jun'25	Sep'25	Dec'25	Mar'26	Mar'26
<b>IPM</b>	<b>2,565</b>	<b>100.0</b>	<b>9.9</b>	<b>9.0</b>	<b>8.3</b>	<b>9.6</b>	<b>7.5</b>	<b>8.8</b>	<b>7.3</b>	<b>11.7</b>	<b>11.5</b>	<b>10.7</b>
Cardiac	344	13.4	14.3	12.5	12.2	12.1	10.4	12.6	13.0	16.9	15.8	14.9
Anti-Infectives	265	10.3	4.8	5.9	8.2	9.0	3.9	6.6	6.5	4.0	3.9	2.3
Gastro Intestinal	267	10.4	6.5	11.2	9.7	10.4	10.1	6.9	5.3	9.0	8.8	9.4
Anti Diabetic	233	9.1	12.2	7.6	9.1	9.4	7.0	8.6	9.1	15.5	15.3	14.1
Respiratory	206	8.0	11.8	1.7	2.8	3.9	3.9	12.3	11.9	12.4	8.8	6.8
Pain / Analgesics	200	7.8	7.9	8.4	7.7	11.0	6.6	7.0	7.2	8.4	11.4	11.5
Vitamins/Minerals/Nutrients	201	7.8	9.9	9.1	8.2	11.3	7.7	8.1	7.6	11.7	13.6	13.2
Derma	174	6.8	6.8	9.9	9.8	12.4	7.5	6.1	5.3	9.2	9.1	8.5
Neuro / Cns	156	6.1	10.6	8.5	9.4	8.6	8.9	10.2	9.5	12.7	12.0	11.0
Gynaec.	123	4.8	8.8	6.9	3.1	5.9	3.7	5.6	5.8	11.8	11.4	11.2
Antineoplast/Immunomodulator	77	3.0	24.5	21.3	12.2	11.6	11.3	14.1	18.1	27.6	31.2	28.2
Ophthalm / Otologicals	49	1.9	9.2	5.5	-4.0	11.2	8.0	8.6	8.0	11.1	11.5	11.1
Urology	59	2.3	11.0	13.7	13.2	14.7	13.6	10.7	10.5	14.4	10.0	8.0
Hormones	39	1.5	10.4	7.2	5.2	6.5	6.1	9.1	10.2	12.3	10.2	8.7

Note: VMN: Vitamin/Minerals/Nutrients; Source: IQVIA, MOFSL

**Exhibit 6: Acute as a percentage of total sales and growth rate on MAT basis in Mar'26**



Source: MOFSL, IQVIA

**Exhibit 7: Torrent tops Semaglutide generics segment in Mar '26**

Brands	Type	Company	Mar'26 Value (INRm)	Mar'26 Quantity (in '000)
SEMALIX	Pen	Torrent	15.1	9.0
SEMBOLIC	Injection	Torrent	12.7	5.7
SEMANEXT	Injection	Lupin	12	5.4
USEMA	Pen	USV	6.6	3.4
OBEDA	Pen	DRRD	6.4	4.1
SEMATRINITY	Pen	Sun	5.4	3.9
SEMAGLYN	Injection	Zydus	4.8	2.2
SEMASIZE	Pen	Alkem	4.5	5.5
NOVELTREAT	Pen	Sun	3.9	2.5
SEMALIX	Oral	Torrent	3.8	30.0
SEMBOLIC	Oral	Torrent	3.8	28.6
SUNDAE	Vial	Eris	3.6	7.2
OLYMVIQ	Pen	DRRD	3	1.8
GLIPIQ	Vial	Glenmark	1.5	3.1
SEMANAT	Vial	NATCO	1.4	3.0

Source: MOFSL, IQVIA



# Sun Pharma

Secondary sales grew 12.5% YoY in Mar'26 vs. 14.6% in Feb'26. Exceptional growth in Pantocid/Rosuvas/Sompraz-D; strong growth in all other major brands, except Volini/Moxclay.

Exceptional growth in Anti-Diabetic/Cardiac/Pain was partially offset by subdued performance in Anti-Infectives.

Price and volume growth drove majority of the growth for MAT Mar'26 basis.

**Exhibit 8: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>2,06,878</b>	<b>11.8</b>	<b>100.0</b>	<b>13.6</b>	<b>12.5</b>
Rosuvas	Cardiac	5,999	15.4	32.9	23.7	25.0
Levipil	Neuro / Cns	4,722	10.2	36.9	15.1	13.0
Gemer	Anti Diabetic	3,707	8.5	10.0	12.4	13.7
Susten	Gynaec.	3,618	14.3	34.4	13.3	15.3
Pantocid	Gastro Intestinal	3,618	18.3	20.6	30.7	26.9
Pantocid-D	Gastro Intestinal	3,281	11.8	17.6	15.5	14.6
Volini	Pain / Analgesics	3,150	-4.6	30.0	-0.3	2.0
Sompraz-D	Gastro Intestinal	3,132	16.5	28.7	20.5	16.9
Montek-Lc	Respiratory	3,033	19.7	20.4	17.8	10.8
Moxclav	Anti-Infectives	2,601	4.8	5.1	1.1	-0.7


Three-months: Jan'26-Mar'26 Source: IQVIA, MOFSL

**Exhibit 9: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>11.8</b>	<b>13.6</b>	<b>12.5</b>
Neuro / Cns	17.5	12.7	14.9	13.8
Cardiac	17.2	14.1	17.7	16.3
Gastro Intestinal	13.3	12.8	15.8	14.0
Anti Diabetic	8.2	17.2	20.3	19.9
Pain / Analgesics	7.8	10.0	14.5	16.3
Anti-Infectives	7.6	2.7	0.7	0.5


Source: IQVIA, MOFSL

**Exhibit 10: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 11: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL

# Cipla

# Cipla

Secondary sales grew 5.9% YoY in Mar'26 vs. 10.5% in Jan'26. Among the top 10 drugs, decline in Asthalin/Ibugesic Plus and subdued performance of Duolin/Seroflo/Urimax-D dragged down the overall performance despite healthy growth in Montair-Lc/Budecort in Mar'26.

**Exhibit 12: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>1,44,282</b>	<b>8.5</b>	<b>100.0</b>	<b>9.2</b>	<b>5.9</b>
Foracort	Respiratory	10,318	14.2	60.9	16.2	10.9
Duolin	Respiratory	6,443	11.6	84.4	2.5	0.2
Budecort	Respiratory	5,532	13.5	80.3	17.5	19.1
Dytor	Cardiac	4,204	25.2	88.0	22.3	9.3
Montair-Lc	Respiratory	3,797	23.1	21.2	30.2	29.2
Asthalin	Respiratory	3,144	8.1	99.4	-8.3	-11.8
Seroflo	Respiratory	2,916	-5.2	70.6	4.1	4.4
Ibugesic Plus	Pain / Analgesics	2,894	4.8	70.9	-1.3	-7.2
Dytor Plus	Cardiac	2,475	25.5	87.0	22.4	10.9
Urimax-D	Urology	2,436	10.5	45.4	8.3	4.9

Three-months: Jan'26-Mar'26 Source: IQVIA, MOFSL

Subdued performance in all key therapies except Anti-Diabetic.


Overall growth was majorly led by price growth on MAT Mar'26 basis.

**Exhibit 13: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>8.5</b>	<b>9.2</b>	<b>5.9</b>
Respiratory	37.5	10.9	8.9	7.1
Anti-Infectives	13.6	5.3	7.7	2.7
Cardiac	11.7	12.1	10.0	1.4
Anti Diabetic	5.4	17.3	27.9	20.9
Pain / Analgesics	5.3	4.2	5.9	8.8
Gastro Intestinal	5.1	-0.2	5.2	6.1


Source: IQVIA, MOFSL

**Exhibit 14: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 15: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



## Zydus Lifesciences

Secondary sales grew 10.8% YoY in Mar'26 vs. 10.8% in Feb'26. Strong double-digit performance in Lipaglyn/Atorya/Bilypsa; offset by significant decline in Amicin/Monotax.

Healthy performance in Antineoplast/Cardiac was partially offset by decline in AI/Gastro.

Overall growth was majorly driven by contribution from new launches and pricing benefit on MAT basis in Mar'26.

**Exhibit 16: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>73,765</b>	<b>10.1</b>	<b>100.0</b>	<b>11.0</b>	<b>10.8</b>
Lipaglyn	Cardiac	3,383	40.6	60.9	42.1	49.0
Deriphyllin	Respiratory	2,346	11.5	99.5	4.9	1.3
Atorva	Cardiac	2,241	23.0	22.5	20.8	17.2
Thrombophob	Others	2,089	500.7	93.7	64.3	10.2
Monotax	Anti-Infectives	1,384	1.0	8.3	-1.9	-5.6
Formonide	Respiratory	1,295	6.7	7.6	6.5	1.7
Amicin	Anti-Infectives	1,237	-6.4	14.9	-8.7	-8.7
Skinlite	Derma	1,077	1.2	32.9	7.6	2.0
Bilypsa	Cardiac	1,034	37.8	18.6	44.3	43.8
Deca Durabolin	Hormones	995	0.8	65.0	8.8	19.5

Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 17: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100</b>	<b>10.1</b>	<b>11.0</b>	<b>10.8</b>
Cardiac	16.1	20.1	22.4	24.0
Respiratory	14.2	13.6	10.3	7.3
Anti-Infectives	11.9	-0.9	-5.8	-6.0
Antineoplast/Immunomodulator	9.6	35.1	47.7	53.2
Gastro Intestinal	9.0	1.5	-3.6	-6.9
Pain / Analgesics	7.5	6.9	4.0	4.1


Source: IQVIA, MOFSL

**Exhibit 18: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 19: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Alkem

Secondary sales grew 11.1% YoY in Mar'26 vs. 11.7% in Feb'26. Strong double-digit performance in Pan/Clavam/Uprise-D3; partially offset by decline in Taxim-O/A To Z Ns/Xone and subdued performance in Pipzo.

Outperformance in multiple therapies partially offset by subdued performance in Anti-Infectives/Neuro.

Price growth and new launches majorly contributed to overall YoY growth on MAT basis in Mar'26.

**Exhibit 20: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>99,512</b>	<b>8.7</b>	<b>100</b>	<b>11.0</b>	<b>11.1</b>
Pan	Gastro Intestinal	7,858	13.4	47.7	21.3	26.9
Clavam	Anti-Infectives	6,869	12.3	14.5	13.0	13.8
Pan-D	Gastro Intestinal	6,310	2.8	33.9	6.6	11.9
Taxim-O	Anti-Infectives	3,389	-0.2	19.7	-1.2	-3.1
A To Z Ns	Vitamins/Minerals/Nutrients	3,358	7.4	10.0	-1.0	-3.5
Uprise-D3	Vitamins/Minerals/Nutrients	2,978	24.2	22.2	16.1	15.7
Pipzo	Anti-Infectives	2,573	9.7	24.5	6.3	2.4
Xone	Anti-Infectives	2,501	-3.9	15.0	-1.5	-2.4
Sumo-L	Pain / Analgesics	2,059	21.2	21.8	25.8	27.5
Gemcal	Pain / Analgesics	1,895	5.8	18.2	12.9	19.9

Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 21: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>8.7</b>	<b>11.0</b>	<b>11.1</b>
Anti-Infectives	32.2	3.8	2.5	2.5
Gastro Intestinal	19.9	8.0	13.1	15.6
Vitamins/Minerals/Nutrients	12.7	18.3	20.2	19.5
Pain / Analgesics	10.7	10.0	16.6	17.6
Anti Diabetic	5.0	14.6	21.3	20.4
Neuro / Cns	3.9	7.5	6.7	4.4


Source: IQVIA, MOFSL

**Exhibit 22: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 23: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Lupin

Lupin's secondary sales grew 14.6% YoY in Mar'26 vs. 13.8% in Feb'26. Strong outperformance in Huminsulin/Tonact/Telekast-L was partly offset by muted growth in Rablet-D.

Strong performance in Cardiac/Respiratory/Gynaec, partially offset by subdued performance in Gastro/Anti-infective.

Overall growth was led by volume growth and price benefit on MAT Mar'26

**Exhibit 24: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>88,062</b>	<b>10.5</b>	<b>100.0</b>	<b>14.8</b>	<b>14.6</b>
Gluconorm-G	Anti Diabetic	3,940	9.9	10.7	13.4	11.0
Budamate	Respiratory	2,876	17.2	17.0	11.9	9.2
Huminsulin	Anti Diabetic	2,702	24.4	10.6	43.6	47.7
Ivabrad	Cardiac	1,785	12.5	60.2	12.5	8.6
Rablet-D	Gastro Intestinal	1,421	9.7	10.9	-1.7	0.0
Tonact	Cardiac	1,154	7.5	11.6	9.8	20.8
Telekast-L	Respiratory	1,090	15.3	6.7	15.9	18.4
Cetil	Anti-Infectives	1,017	15.2	8.7	18.3	13.3
Signoflam	Pain / Analgesics	986	8.4	8.9	17.2	28.6
Novostat	Cardiac	936	15.9	5.1	17.7	18.9


Three-months: Jan'26-Mar'26 Source: IQVIA, MOFSL

**Exhibit 25: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>10.5</b>	<b>14.8</b>	<b>14.6</b>
Cardiac	24.5	17.0	20.9	20.4
Anti Diabetic	20.1	7.4	14.2	13.7
Respiratory	15.4	18.9	22.1	22.5
Gastro Intestinal	8.5	6.3	6.3	6.1
Anti-Infectives	6.5	5.1	8.0	7.6
Gynaec	4.9	7.6	15.9	15.1


Source: IQVIA, MOFSL

**Exhibit 26: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 27: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



## GlaxoSmithKline Pharmaceuticals

GSK's secondary sales grew 7.8% YoY in Mar'26 vs. 8.7% in Mar'26. Among the top 10 drugs, decline in Eltroxin and subdued performance of Ceftum/T-Bact/Augmentin dragged down the overall performance in Mar'26.

Weaker trends in Hormones/Anti-infective/Derma affected overall growth for Mar'26.

YoY growth was impacted by volume contraction and muted contribution from new launches, despite priced growth in MAT Mar'26.

**Exhibit 28: Top 10 drugs**

Drug	Therapy	Value (INR m)	MAT Mar'26		Growth (%)	
			Growth (%)	Market share Last 3M (%)	Mar'26	Mar'26
<b>Total</b>		<b>55,929</b>	<b>6.9</b>	<b>100.0</b>	<b>9.6</b>	<b>7.8</b>
Augmentin	Anti-Infectives	9,397	12.2	24.4	8.2	6.8
Calpol	Pain / Analgesics	4,464	5.3	28.4	12.7	10.0
T-Bact	Derma	4,344	10.8	79.4	14.9	6.3
Ceftum	Anti-Infectives	2,956	14.6	31.7	3.0	0.0
Eltroxin	Hormones	2,698	4.0	20.2	3.3	-4.0
Betnovate-N	Derma	2,630	-0.5	99.9	9.6	15.3
Betnovate-C	Derma	2,625	-2.3	99.9	7.3	8.7
Neosporin	Derma	2,382	13.4	93.5	25.5	28.4
Infanrix Hexa	Vaccines	1,982	7.4	44.1	24.7	22.5
Ccm	Vitamins/Minerals/Nutrients	1,742	9.9	13.5	11.7	10.3

Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 29: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>6.9</b>	<b>9.6</b>	<b>7.8</b>
Derma	28.6	3.6	8.7	8.1
Anti-Infectives	25.0	10.4	5.5	4.5
Vaccines	13.3	11.7	21.9	14.9
Pain / Analgesics	10.5	5.1	11.7	10.4
Hormones	7.3	3.0	6.0	-3.1
Vitamins/Minerals/Nutrients	6.5	6.8	7.3	10.5

Source: IQVIA, MOFSL

**Exhibit 30: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 31: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



## Glenmark Pharma

Secondary sales grew 12.7% YoY in Mar'26 vs. 13.1% in Feb'26. Among the top 10 drugs, Milibact/Candid/Candid-B/ Telma posted strong growth, offsetting decline in Alex/Ascoril +.

Exceptional growth in Antineoplast/Anti-Infective/ Cardiac led overall YoY growth, which was partially offset by decline in Anti-diabetic.

Overall performance was driven by both price and volume growth on MAT basis in Mar'26.

**Exhibit 32: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>56,447</b>	<b>13.6</b>	<b>100.0</b>	<b>12.5</b>	<b>12.7</b>
Telma	Cardiac	6,237	19.9	43.0	15.6	15.6
Telma-H	Cardiac	4,616	16.1	43.2	6.1	8.4
Telma-Am	Cardiac	4,290	13.5	30.9	11.0	8.2
Ascoril-Ls	Respiratory	3,142	18.2	26.0	8.4	6.6
Candid	Derma	2,453	4.3	65.7	10.5	17.7
Candid-B	Derma	1,797	5.8	84.0	10.2	15.2
Milibact	Anti-Infectives	1,481	25.8	11.3	26.4	23.5
Alex	Respiratory	1,424	9.4	5.4	0.0	-7.2
Ascoril +	Respiratory	1,284	4.0	5.0	-3.6	-9.2
Ascoril D Plus	Respiratory	1,257	10.7	4.9	7.6	11.4

Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 33: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>13.6</b>	<b>12.5</b>	<b>12.7</b>
Cardiac	34.8	17.7	14.3	14.5
Derma	24.5	8.0	8.6	10.1
Respiratory	21.5	15.4	9.5	6.3
Anti-Infectives	9.2	16.0	27.3	25.9
Anti Diabetic	4.2	-4.8	-4.2	-2.1
Antineoplast/Immunomodulator	1.5	65.0	52.9	56.5


Source: IQVIA, MOFSL

**Exhibit 34: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 35: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Dr. Reddy's Laboratories

Secondary sales grew 18.2% YoY in Mar'26 vs. 14.3% in Feb'26. Strong outperformance in majority of the key brands.

Healthy double-digit growth across key therapies drive superior performance in Mar'26.

Price growth followed by new launches-led overall growth on MAT basis in Mar'26.

**Exhibit 36: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>82,179</b>	<b>12.1</b>	<b>100.0</b>	<b>15.2</b>	<b>18.2</b>
Atarax	Respiratory	2,623	9.6	73.0	16.0	20.4
Ketorol	Pain / Analgesics	2,487	12.8	91.3	18.0	13.8
Voveran	Pain / Analgesics	2,470	6.0	87.3	15.4	22.5
Econorm	Gastro Intestinal	2,414	6.7	91.6	13.3	14.1
Omez	Gastro Intestinal	2,225	2.6	78.5	9.2	18.0
Hexaxim	Vaccines	2,079	21.0	46.3	19.5	18.2
Venusia	Derma	1,871	14.8	8.5	12.8	10.2
Zedex	Respiratory	1,777	20.3	22.7	26.8	32.4
Menactra	Vaccines	1,770	19.6	80.2	16.5	21.2
Omez D+	Gastro Intestinal	1,688	12.8	15.5	18.0	24.4

Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 37: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100</b>	<b>12.1</b>	<b>15.2</b>	<b>18.2</b>
Gastro Intestinal	15.3	8.1	14.1	17.0
Respiratory	13.8	13.9	13.5	16.4
Pain / Analgesics	10.5	14.1	22.5	23.5
Cardiac	9.1	9.7	14.3	19.0
Vaccines	7.9	14.3	11.7	15.1
Derma	7.8	12.4	13.5	16.4


Source: IQVIA, MOFSL

**Exhibit 38: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 39: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Torrent Pharma

Secondary sales grew 11.3% YoY in Mar'26 vs. 13.9% in Feb'26. Exceptional outperformance in majority of the Top-10 brands, partially offset by decline in Rantac/Metrogl in Mar'26.

**Exhibit 40: Top 10 drugs**

Drug	Therapy	MAT Mar'26		Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M Mar'26
<b>Total</b>		<b>1,18,583</b>	<b>10.5</b>	<b>100.0</b>	<b>12.2</b>
Cilacar	Cardiac	5,432	17.4	55.1	20.4
Shelcal	Vitamins/Minerals/Nutrients	3,618	7.6	34.1	19.4
Chymoral	Pain / Analgesics	3,559	10.0	88.8	22.7
Rantac	Gastro Intestinal	3,294	-7.2	35.6	-12.8
Cilacar-T	Cardiac	2,873	27.6	37.1	25.7
Nexpro-Rd	Gastro Intestinal	2,744	14.0	25.2	13.9
Nikorin	Cardiac	2,618	21.2	53.4	25.8
Nicardia	Cardiac	2,576	25.6	94.4	22.0
Shelcal Xt	Vitamins/Minerals/Nutrients	2,422	3.6	18.8	10.2
Metrogl	Anti-Parasitic	2,297	2.4	78.9	-10.2

Three-months: Jan'26-Mar'26 Source: IQVIA, MOFSL

Outperformance in Pain/VMN/Cardiac/Neuro in Mar'26.


**Exhibit 41: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>10.5</b>	<b>12.2</b>	<b>11.3</b>
Cardiac	33.0	15.1	17.4	15.5
Gastro Intestinal	19.1	7.8	7.4	7.8
Neuro / Cns	11.3	12.3	14.8	14.4
Vitamins/Minerals/Nutrients	7.6	10.6	19.2	18.0
Anti Diabetic	7.0	9.6	9.1	7.6
Pain / Analgesics	6.2	9.7	18.6	19.5


Source: IQVIA, MOFSL

Growth was majorly driven by price and volume growth on MAT Mar'26.

**Exhibit 42: Acute vs. Chronic (MAT growth)**



**Exhibit 43: Growth distribution (%) (MAT Mar'26)**





## Alembic Pharmaceuticals

**Exhibit 44: Top 10 drugs**

Alembic's secondary sales declined 1.4% YoY in Mar'26 vs. 2.5% growth in Feb'26. Among the top 10 drugs, decline in Wikoryl/Athrocin/Azithral dragged down the overall performance despite healthy performance in Isofit/Cetani-T/Richar Cr.

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>32350</b>	<b>1.1</b>	<b>100.0</b>	<b>0.3</b>	<b>-1.4</b>
Azithral	Anti-Infectives	4194	0.3	29.5	-9.5	-15.1
Wikoryl	Respiratory	1266	2.5	8.3	-8.7	-15.1
Gestofit	Gynaec.	1178	9.7	11.2	8.8	10.4
Althrocin	Anti-Infectives	1133	-13.3	84.5	-14.0	-16.7
Crina-Ncr	Gynaec.	989	12.3	29.5	12.4	8.7
Isofit	Gynaec.	915	19.5	6.5	19.6	25.2
Brozeet-Ls	Respiratory	777	9.6	6.4	4.1	-0.4
Cetani-T	Cardiac	669	20.5	8.6	19.6	20.1
Tellzy-Am	Cardiac	663	2.9	4.8	8.9	11.3
Richar Cr	Gynaec.	644	2.4	3.7	7.7	17.7

\* Three-months: Jan'26-Mar'26

Source: IQVIA, MOFSL

Decline in Gastro/AI/Respiratory and a weaker trend in Anti-Diabetic dragged overall growth for Mar'26.


**Exhibit 45: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>1.1</b>	<b>0.3</b>	<b>-1.4</b>
Anti-Infectives	19.5	-2.8	-10.7	-15.5
Cardiac	16.7	5.0	7.2	7.1
Gynaec.	16.3	7.4	12.6	13.8
Respiratory	12.9	3.1	-4.3	-9.7
Gastro Intestinal	9.5	-9.5	-8.0	-8.2
Anti Diabetic	8.3	0.6	0.7	1.0

Source: IQVIA, MOFSL


Volume decline impacted YoY growth despite price growth for MAT Mar'26.

**Exhibit 46: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 47: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Ipca Laboratories

**Exhibit 48: Top 10 drugs**

Secondary sales grew 11.1% YoY in Mar'26 vs. 14.2% in Feb'26. Robust growth in Ctd-T/Folitrax/Tfct-Nib/Zerodol-Sp/Saaz led the overall growth in Mar'26.

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>53576</b>	<b>10.7</b>	<b>100.0</b>	<b>13.6</b>	<b>11.1</b>
Zerodol-Sp	Pain / Analgesics	6934	13.4	62.7	20.2	21.4
Zerodol-P	Pain / Analgesics	3150	5.1	51.0	6.9	2.2
Hcqs	Pain / Analgesics	2135	5.1	82.6	7.7	2.8
Folitrax	Antineoplast/Immunomodulator	1807	23.2	85.7	24.0	17.2
Ctd-T	Cardiac	1394	18.5	21.6	24.1	22.0
Zerodol-Th	Pain / Analgesics	1387	5.3	60.1	11.7	9.4
Solvin Cold	Respiratory	1078	17.7	7.5	9.5	3.0
Tfct-Nib	Pain / Analgesics	958	16.6	24.0	26.8	24.7
Ctd	Cardiac	920	11.9	98.2	14.8	8.6
Saaz	Gastro Intestinal	844	17.5	60.0	17.7	15.2

\* Three-months: Jan'26-Mar'26

Source: IQVIA, MOFSL

Strong performance in Antineoplast/Pain/Derma led the growth during Mar'26, partially offset by subdued growth in AI.


Price and volume were the key growth drivers for MAT Mar'26.

**Exhibit 49: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>10.7</b>	<b>13.6</b>	<b>11.1</b>
Pain / Analgesics	38.8	10.7	14.8	13.4
Cardiac	12.8	9.6	13.5	11.8
Anti-Infectives	6.8	3.2	1.7	-5.3
Antineoplast/Immunomodulator	6.4	28.3	29.6	23.8
Derma	5.5	6.8	15.2	13.0
Urology	4.9	14.6	18.2	17.9


Source: IQVIA, MOFSL

**Exhibit 50: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 51: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



## Eris Lifesciences

Secondary sales grew 8.0% YoY in Mar'26 vs. 10.2% in Feb'26. Healthy growth in Cyblex Mv/Insugen led the uptick despite a double-digit decline in Hertraz.

Healthy performance VMN/Antineoplast/Gynae led the expansion in therapies in Mar'26.

Growth was driven by price hikes and new launches on MAT basis in Mar'26.

**Exhibit 52: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>33256</b>	<b>7.4</b>	<b>100.0</b>	<b>8.4</b>	<b>8.0</b>
Renerve Plus	Vitamins/Minerals/Nutrients	1506	5.7	10.4	10.7	10.8
Glimisave Mv	Anti Diabetic	1435	1.8	10.6	2.9	5.3
Insugen	Anti Diabetic	1303	26.6	5.1	24.7	18.5
Basalog	Anti Diabetic	1129	8.5	8.9	7.8	7.5
Glimisave-M	Anti Diabetic	976	-2.6	2.6	-4.8	0.5
Cyblex Mv	Anti Diabetic	575	21.6	51.7	25.0	32.6
Eritel Ln	Cardiac	542	14.3	7.0	13.4	10.3
Hertraz	Antineoplast/Immunomodulator	448	72.4	6.9	-49.5	-56.0
Xsulin	Anti Diabetic	446	67.4	1.8	77.7	61.5
Remylin D	Vitamins/Minerals/Nutrients	438	-6.6	10.1	-7.3	-8.4

\* Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSI

**Exhibit 53: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>7.4</b>	<b>8.4</b>	<b>8.0</b>
Anti Diabetic	33.4	9.8	10.7	10.1
Cardiac	15.8	9.1	15.0	13.4
Derma	13.3	14.0	11.0	7.9
Vitamins/Minerals/Nutrients	11.8	3.5	13.2	14.0
Antineoplast/Immunomodulator	6.4	13.0	4.2	18.9
Gynae.	4.9	12.3	16.1	20.9

Source: IQVIA, MOFSI

**Exhibit 54: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSI

**Exhibit 55: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSI



## Abbott India

Secondary sales grew 11.3% YoY in Mar'26 vs. 11.6% in Feb'26. Among the top 10 drugs, Robust growth in Cremaffin Plus/Influvac/Thyronorm led the uptick in Mar'26 despite a double-digit decline in rybelsus/mixtard.

Healthy performance in Gastro/Cardiac/Hormones led the growth in Mar'26.

Overall growth on MAT basis was mainly driven by price hikes followed by NP launches and volume growth in Mar'26.

**Exhibit 56: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>161866</b>	<b>7.8</b>	<b>100.0</b>	<b>9.3</b>	<b>11.3</b>
Thyronorm	Hormones	7602	12.9	56.8	13.0	12.4
Udiliv	Hepatoprotectives	7371	12.0	52.1	4.2	5.0
Ryzodeg	Anti Diabetic	7081	11.0	27.8	12.7	8.8
Mixtard	Anti Diabetic	6161	-23.3	24.2	-37.9	-37.9
Rybelsus	Anti Diabetic	4590	9.7	26.2	-20.3	-23.8
Duphaston	Gynaec.	4075	7.2	29.1	6.2	4.0
Duphalac	Gastro Intestinal	3957	7.3	56.0	6.8	7.3
Cremaffin Plus	Gastro Intestinal	3935	12.8	52.2	21.1	31.6
Influvac	Vaccines	3702	20.1	66.3	22.4	44.9
Novomix	Anti Diabetic	3534	-4.1	13.9	-3.2	-5.7

\* Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 57: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>7.8</b>	<b>9.3</b>	<b>11.3</b>
Anti Diabetic	23.2	-2.0	-4.7	-6.1
Gastro Intestinal	16.1	16.0	23.7	26.8
Vitamins/Minerals/Nutrients	9.0	10.9	16.0	13.7
Anti-Infectives	7.7	5.8	9.1	13.2
Cardiac	7.2	15.8	13.2	15.4
Hormones	6.8	12.1	13.1	13.6

Source: IQVIA, MOFSL

**Exhibit 58: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 59: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



## Mankind Pharma

Mankind's secondary sales grew 11.5% YoY in Mar'26 vs. 4.7% in Feb'26. Robust Growth in Dydroboon/Prega news/Telmikind-Am drove the overall growth in Mar'26.

**Exhibit 60: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>1,21,558</b>	<b>8.2</b>	<b>100.0</b>	<b>8.7</b>	<b>11.5</b>
Manforce	Urology	5,958	10.4	72.1	6.4	10.5
Moxikind-Cv	Anti-Infectives	4,076	4.5	11.4	-0.8	1.2
Amlokind-At	Cardiac	2,998	9.8	39.4	5.5	7.0
Unwanted-Kit	Gynaec.	2,562	3.2	57.0	-6.6	-6.1
Prega News	Others	2,476	8.1	82.6	28.7	13.5
Dydroboon	Gynaec.	2,404	8.2	17.2	20.3	20.3
Telmikind-Am	Cardiac	2,116	22.8	15.3	18.4	21.0
Gudcef	Anti-Infectives	2,084	1.7	17.3	-6.6	-7.4
Glimestar-M	Anti Diabetic	2,060	5.0	5.6	-2.2	-3.9
Candiforce	Derma	2,024	2.0	19.6	0.0	9.0

\* Three-months: Jan'26-Mar'26

Source: IQVIA, MOFSL

Double-digit growth in majority of therapies but a decline in AI during Mar'26.


Overall growth was driven by price hikes followed by volume growth & new launches on MAT basis in Mar'26.

**Exhibit 61: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>8.2</b>	<b>8.7</b>	<b>11.5</b>
Cardiac	15.6	16.0	14.7	20.0
Anti-Infectives	13.0	2.9	-1.1	-0.4
Gynaec.	10.5	8.1	10.8	13.1
Gastro Intestinal	9.4	3.1	9.2	14.2
Anti Diabetic	8.6	12.7	11.6	12.6
Vitamins/Minerals/Nutrients	8.5	7.9	12.5	15.8


Source: IQVIA, MOFSL

**Exhibit 62: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 63: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Macleods Pharma

Secondary sales grew 9.1% YoY in Mar'26 vs. 7.9% in Feb'26. Decline in Panderm++/Meromac and muted growth in Thyrox/Accuzon-Plus dragged down overall performance in Mar'26.

Moderate performance registered in AI/Pain/Hormones during Mar'26.

Price hikes and volume growth were the key growth drivers followed by product launches for MAT Mar'26 basis.

**Exhibit 64: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>84,370</b>	<b>10.4</b>	<b>100.0</b>	<b>9.8</b>	<b>9.1</b>
Meromac	Anti-Infectives	2,766	5.1	17.8	3.9	-0.2
Thyrox	Hormones	2,674	13.1	20.0	6.3	2.6
Omnacortil	Hormones	2,410	19.3	66.6	13.1	14.9
Megalis	Urology	1,722	16.7	60.2	22.8	16.5
Panderm ++	Derma	1,699	-4.6	49.2	1.2	-2.2
Geminor-M	Anti Diabetic	1,677	17.4	4.5	13.1	8.1
Defcort	Hormones	1,618	9.8	53.0	11.3	10.9
It-Mac	Derma	1,608	12.3	15.6	7.7	9.6
Maczone-Plus	Anti-Infectives	1,569	24.3	12.0	15.4	11.6
Accuzon-Plus	Anti-Infectives	1370	32.2	10.5	13.0	6.2

\* Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 65: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>10.4</b>	<b>9.8</b>	<b>9.1</b>
Anti-Infectives	29.7	10.3	7.7	4.0
Cardiac	13.2	13.6	13.3	14.3
Respiratory	9.6	18.6	14.1	11.7
Hormones	8.9	13.4	9.2	8.0
Pain / Analgesics	7.9	8.4	7.4	9.9
Anti Diabetic	6.2	12.0	11.5	12.1


Source: IQVIA, MOFSL

**Exhibit 66: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 67: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



# Ajanta Pharma

Secondary sales grew 14.5% YoY in Mar'26 vs. 15.5% in Feb'26. Robust growth in Ivrea/Met XI 3D/Feburic led the overall growth in Mar'26.

Strong double-digit growth in all therapies was offset by moderate YoY growth in Respiratory/Cardiac during Mar'26.

Price hikes and new product launches led the overall growth followed by volume growth for MAT Mar'26.

**Exhibit 68: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>20693</b>	<b>13.1</b>	<b>100.0</b>	<b>15.1</b>	<b>14.5</b>
Met XI	Cardiac	1764	2.6	24.1	5.9	6.3
Feburic	Pain / Analgesics	980	8.9	18.8	9.3	17.3
Atorfit-Cv	Cardiac	752	-3.5	16.6	0.4	1.2
Melacare	Derma	713	-6.0	21.8	-7.2	2.4
Cinod	Cardiac	563	5.6	5.7	5.9	2.4
Met XI Trio	Cardiac	544	12.2	22.9	17.0	7.7
Met XI Am	Cardiac	426	5.7	13.4	12.5	13.5
Rosufit-Cv	Cardiac	384	1.4	9.0	3.7	-0.5
Ivrea	Derma	362	15.5	64.3	31.5	33.5
Met XI 3D	Cardiac	331	13.3	25.6	18.7	21.2

\* Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 69: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>13.1</b>	<b>15.1</b>	<b>14.5</b>
Cardiac	32.7	6.6	10.0	8.5
Ophthal / Otologicals	27.6	14.4	16.0	15.5
Derma	21.2	13.9	11.1	10.9
Pain / Analgesics	8.9	11.5	18.1	24.5
Anti Diabetic	2.5	20.2	25.4	16.2
Respiratory	1.6	10.3	6.4	5.2


Source: IQVIA, MOFSL

**Exhibit 70: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 71: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL



Secondary sales grew 2.4% YoY in Mar'26 vs. 4.3% in Feb'26. Decline in Metpure-XI/Clexane/Amaryl-M/Maxtra/Bevon and subdued performance in Zostum dragged overall performance despite strong performance in Orofer-Xt/Orofer Fcm/Spegra in Mar'26.

Contraction in Anti-Diabetic/AI/Cardiac during Mar'26.

Price hike is the primary growth driver on MAT Mar'26 basis.

## Emcure

**Exhibit 72: Top 10 drugs**

Drug	Therapy	MAT Mar'26			Growth (%)	
		Value (INR m)	Growth (%)	Market share (%)	Last 3M	Mar'26
<b>Total</b>		<b>57,093</b>	<b>5.1</b>	<b>100.0</b>	<b>3.7</b>	<b>2.4</b>
Orofer-Xt	Gynaec.	2,810	7.5	16.8	14.0	21.7
Zostum	Anti-Infectives	2,587	12.7	29.9	7.9	0.2
Bevon	Vitamins/Minerals/Nutrients	1,683	3.3	22.7	-0.3	-0.4
Amaryl M	Anti Diabetic	1,646	-7.2	4.5	-9.5	-10.3
Orofer Fcm	Gynaec.	1,534	22.1	15.9	23.1	15.6
Maxtra	Respiratory	1,187	0.0	11.7	-12.4	-11.8
Clexane	Cardiac	1,067	-3.9	12.1	-10.5	-14.4
Metpure-XI	Cardiac	974	0.1	86.1	-13.9	-10.9
Amaryl	Anti Diabetic	835	-0.2	27.0	7.6	2.5
Spegra	Antiviral	824	54.6	32.3	48.0	38.4

\* Three-months: Jan'26-Mar'26


Source: IQVIA, MOFSL

**Exhibit 73: Therapy mix (%)**

	Share	MAT growth (%)	3M*	Mar'26
<b>Total</b>	<b>100.0</b>	<b>5.1</b>	<b>3.7</b>	<b>2.4</b>
Cardiac	19.1	3.2	-1.7	-1.5
Gynaec.	17.9	8.6	7.1	9.7
Anti-Infectives	11.6	1.9	-4.1	-9.2
Anti Diabetic	7.9	-8.6	-8.5	-9.1
Pain / Analgesics	6.6	4.8	4.7	3.4
Antineoplast/Immunomodulator	6.4	32.2	48.5	30.3


Source: IQVIA, MOFSL

**Exhibit 74: Acute vs. Chronic (MAT growth)**



Source: IQVIA, MOFSL

**Exhibit 75: Growth distribution (%) (MAT Mar'26)**



Source: IQVIA, MOFSL

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online-reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

**Analyst Certification**

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

**Terms & Conditions:**

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

**Disclaimer:**

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CD SL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI:

ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.